Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INCNBIX · Entity 2655 | Chief Commercial Officer | September 11, 2026 | September 15, 2026 |
| aTYR PHARMA INCATYR · Entity 7233 | Director | May 11, 2026 | May 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NEUROCRINE BIOSCIENCES INC
Report date September 11, 2026 · Filed September 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 67,297 |
Ending reported balance
After 2026-09-11 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-11 · Grant · Acquired 6,275 · Balance 70,683 F1: The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026. Row 2 · 2026-09-11 · Tax withholding · Disposed 3,386 · Balance 67,297 F2: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026.
F2: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold.
aTYR PHARMA INC
Report date May 11, 2026 · Filed May 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.95 · Expires 2036-05-11 | Direct | 50,000 |
Reported balance
After 2026-05-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-11 · Grant · Acquired 50,000 · Balance 50,000 F1: The option, granted pursuant to the Issuer's non-employee director compensation policy, vests in full on the earlier of (i) May 11, 2027 or (ii) the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Board of Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: The option, granted pursuant to the Issuer's non-employee director compensation policy, vests in full on the earlier of (i) May 11, 2027 or (ii) the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Board of Directors.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 08, 2022 Filed Feb 9, 2022 23:53 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 980 | $79.67 | $78,072.58 |
DisclosureSEC source: 0001209191-22-008204 · doc4.xml · nonDerivative · entry 4 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,338 F7 · kind: Sale of 980 shares of common stock issued upon vesting of 1,859 restricted stock units on February 8, 2022 to cover payroll and withholding taxes, with the balance of the shares (879) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F8 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $79.08 to $80.21. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F9 · balance_after: Includes an aggregate of 146 shares purchased on August 31, 2021 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan. Read SEC document |
| February 07, 2022 Filed Feb 9, 2022 23:53 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 1,280 | $80.78 | $103,398.40 |
DisclosureSEC source: 0001209191-22-008204 · doc4.xml · nonDerivative · entry 3 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,459 F5 · kind: Sale of 1,280 shares of common stock issued upon vesting of 2,430 restricted stock units on February 7, 2022 to cover payroll and withholding taxes, with the balance of the shares (1,150) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F6 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $79.77 to $81.35. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 07, 2022 Filed Feb 9, 2022 23:53 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 2,030 | $80.83 | $164,080.84 |
DisclosureSEC source: 0001209191-22-008204 · doc4.xml · nonDerivative · entry 2 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,309 F3 · kind: Sale of 2,030 shares of common stock issued upon vesting of 3,856 restricted stock units on February 7, 2022 to cover payroll and withholding taxes, with the balance of the shares (1,826) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F4 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $79.72 to $81.37. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 07, 2022 Filed Feb 9, 2022 23:53 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 809 | $80.68 | $65,269.07 |
DisclosureSEC source: 0001209191-22-008204 · doc4.xml · nonDerivative · entry 1 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,483 F1 · kind: Sale of 809 shares of common stock issued upon vesting of 1,538 restricted stock units on February 7, 2022 to cover payroll and withholding taxes, with the balance of the shares (729) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $79.79 to $81.13. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 31, 2022 Filed Feb 3, 2022 01:00 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantRestricted Stock Unit · Derivative | 9,175 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-006585 · doc4.xml · derivative · entry 2 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,175 Underlying: Common Stock · 9,175 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of January 31, 2023, January 31, 2024, January 31, 2025, and January 31, 2026. F3 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of January 31, 2023, January 31, 2024, January 31, 2025, and January 31, 2026. Read SEC document |
| January 31, 2022 Filed Feb 3, 2022 01:00 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantStock Option · Derivative | 62,483 | $0.00 Strike: $79.02 | $0.00 |
DisclosureSEC source: 0001209191-22-006585 · doc4.xml · derivative · entry 1 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,483 Underlying: Common Stock · 62,483 shares Expires 2032-01-31 F1 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on February 28, 2022 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. Read SEC document |
| August 16, 2021 Filed Aug 18, 2021 22:18 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 5,628 | $89.62 | $504,394.87 |
DisclosureSEC source: 0001209191-21-052337 · doc4.xml · nonDerivative · entry 1 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,608 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · balance_after: Includes 137 shares acquired under the Neurocrine Biosciences 2018 Employee Stock Purchase Plan on February 26, 2021. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 02:26 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantRestricted Stock Unit · Derivative | 7,439 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-009128 · doc4.xml · derivative · entry 6 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,439 Underlying: Common Stock · 7,439 shares Expires not disclosed F10 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. F11 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 8, 2022, February 8, 2023, February 8, 2024, and February 8, 2025. F11 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 8, 2022, February 8, 2023, February 8, 2024, and February 8, 2025. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 02:26 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantStock Option · Derivative | 44,632 | $0.00 Strike: $117.63 | $0.00 |
DisclosureSEC source: 0001209191-21-009128 · doc4.xml · derivative · entry 5 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,632 Underlying: Common Stock · 44,632 shares Expires 2031-02-08 F9 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 8, 2021 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 02:26 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 2,030 | $116.84 | $237,186.42 |
DisclosureSEC source: 0001209191-21-009128 · doc4.xml · nonDerivative · entry 4 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,099 F7 · kind: Sale of 2,030 shares of common stock issued upon vesting of 3,856 restricted stock units on February 8, 2021 to cover payroll and withholding taxes, with the balance of the shares (1,826) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F8 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $116.01 to $118.12. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 02:26 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 1,395 | $116.76 | $162,880.06 |
DisclosureSEC source: 0001209191-21-009128 · doc4.xml · nonDerivative · entry 3 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,273 F5 · kind: Sale of 1,395 shares of common stock issued upon vesting of 2,650 restricted stock units on February 8, 2021 to cover payroll and withholding taxes, with the balance of the shares (1,255) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F6 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $116.01 to $117.84. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 02:26 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 845 | $116.89 | $98,775.18 |
DisclosureSEC source: 0001209191-21-009128 · doc4.xml · nonDerivative · entry 2 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,018 F3 · kind: Sale of 845 shares of common stock issued upon vesting of 2,429 restricted stock units on February 8, 2021 to cover payroll and withholding taxes, with the balance of the shares (1,584) maintained by the Reporting Person. The disposition reported in this Form 4 was effected by a broker pursuant to instructions consistent with Rule 10b5-1 at least 60 days prior to the transaction date in Box 3 above. F4 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $115.97 to $117.55. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 08, 2021 Filed Mar 27, 2021 01:48 UTC Amendment | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantStock Option · Derivative | 49,049 | $0.00 Strike: $117.63 | $0.00 |
DisclosureSEC source: 0001209191-21-023368 · doc4a.xml · derivative · entry 1 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,049 Underlying: Common Stock · 49,049 shares Expires 2031-02-08 F1 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 8, 2021 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. Read SEC document |
| February 05, 2021 Filed Feb 10, 2021 02:26 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 809 | $114.03 | $92,247.03 |
DisclosureSEC source: 0001209191-21-009128 · doc4.xml · nonDerivative · entry 1 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,434 F1 · kind: Sale of 809 shares of common stock issued upon vesting of 1,538 restricted stock units on February 5, 2021 to cover payroll and withholding taxes, with the balance of the shares (729) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $111.47 to $116.26. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 26, 2021 Filed Jan 28, 2021 01:58 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 300 | $41.78 Strike: $41.78 | $12,534.00 |
DisclosureSEC source: 0001209191-21-005797 · doc4.xml · derivative · entry 8 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,223 Underlying: Common Stock · 300 shares Expires 2025-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Option granted June 1, 2015 and vested at 25% upon first anniversary (June 1, 2016) and remaining 75% vested in 36 equal monthly installments beginning July 1, 2016. Read SEC document |
| January 26, 2021 Filed Jan 28, 2021 01:58 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 100 | $120.00 | $12,000.00 |
DisclosureSEC source: 0001209191-21-005797 · doc4.xml · nonDerivative · entry 6 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,705 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Read SEC document |
| January 26, 2021 Filed Jan 28, 2021 01:58 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 300 | $120.00 | $36,000.00 |
DisclosureSEC source: 0001209191-21-005797 · doc4.xml · nonDerivative · entry 5 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,805 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Read SEC document |
| January 26, 2021 Filed Jan 28, 2021 01:58 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 300 | $41.78 | $12,534.00 |
DisclosureSEC source: 0001209191-21-005797 · doc4.xml · nonDerivative · entry 4 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,105 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 25, 2021 Filed Jan 28, 2021 01:58 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 3,477 | $41.78 Strike: $41.78 | $145,269.06 |
DisclosureSEC source: 0001209191-21-005797 · doc4.xml · derivative · entry 7 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,523 Underlying: Common Stock · 3,477 shares Expires 2025-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Option granted June 1, 2015 and vested at 25% upon first anniversary (June 1, 2016) and remaining 75% vested in 36 equal monthly installments beginning July 1, 2016. Read SEC document |
| January 25, 2021 Filed Jan 28, 2021 01:58 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 1,600 | $120.03 | $192,044.00 |
DisclosureSEC source: 0001209191-21-005797 · doc4.xml · nonDerivative · entry 3 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,805 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F3 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $120.00 to $120.04. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 25, 2021 Filed Jan 28, 2021 01:58 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 3,477 | $120.03 | $417,327.27 |
DisclosureSEC source: 0001209191-21-005797 · doc4.xml · nonDerivative · entry 2 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,405 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $120.00 to $120.07. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 25, 2021 Filed Jan 28, 2021 01:58 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 3,477 | $41.78 | $145,269.06 |
DisclosureSEC source: 0001209191-21-005797 · doc4.xml · nonDerivative · entry 1 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,882 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 12, 2020 Filed Nov 16, 2020 23:27 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 2,257 | $90.71 | $204,722.99 |
DisclosureSEC source: 0001209191-20-058554 · doc4.xml · nonDerivative · entry 1 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,405 F1 · kind: Sale of 2,257 shares of common stock issued upon vesting of 4,288 performance restricted stock units to cover withholding taxes, with the balance of the shares (2,031) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $88.93 to $91.88. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 23:09 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 20,595 | $35.99 Strike: $35.99 | $741,214.05 |
DisclosureSEC source: 0001209191-20-056981 · doc4.xml · derivative · entry 3 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,775 Underlying: Common Stock · 20,595 shares Expires 2026-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Option granted February 05, 2016 and vested monthly over four years. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 23:09 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 20,595 | $96.53 | $1,987,971.51 |
DisclosureSEC source: 0001209191-20-056981 · doc4.xml · nonDerivative · entry 2 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,374 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $94.68 to $98.80. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 23:09 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 20,595 | $35.99 | $741,214.05 |
DisclosureSEC source: 0001209191-20-056981 · doc4.xml · nonDerivative · entry 1 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,969 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 05, 2020 Filed Aug 7, 2020 22:35 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 2,257 | $118.85 | $268,254.16 |
DisclosureSEC source: 0001209191-20-045725 · doc4.xml · nonDerivative · entry 1 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,374 F1 · kind: Sale of 2,257 shares of common stock issued upon vesting of 4,287 performance restricted stock units to cover withholding taxes, with the balance of the shares (2,030) maintained by the Reporting Person. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $118.21 to $120.56. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| April 24, 2020 Filed Apr 29, 2020 00:33 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 1,934 | $99.45 | $192,337.85 |
DisclosureSEC source: 0001209191-20-026063 · doc4.xml · nonDerivative · entry 1 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,344 F1 · kind: Sale of 1,934 shares of common stock issued upon vesting of 3,675 performance restricted stock units on April 24, 2020 to cover withholding taxes, with the balance of the shares (1,741) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $97.56 to $101.13. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| April 15, 2020 Filed Apr 18, 2020 01:48 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 8,632 | $94.65 | $817,017.94 |
DisclosureSEC source: 0001209191-20-025028 · doc4.xml · nonDerivative · entry 1 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,603 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $92.80 to $95.63. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · balance_after: Includes 148 shares acquired under the Neurocrine Biosciences 2018 Employee Stock Purchase Plan on February 28, 2020. Read SEC document |
| February 07, 2020 Filed Feb 12, 2020 00:08 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 2,030 | $103.32 | $209,747.31 |
DisclosureSEC source: 0001209191-20-008481 · doc4.xml · nonDerivative · entry 1 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,087 F1 · kind: Sale of 2,030 shares of common stock issued upon vesting of 3,855 restricted stock units on February 7, 2020 to cover payroll and withholding taxes, with the balance of the shares (1,825) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $102.24 to $104.05. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 06, 2020 Filed Feb 7, 2020 23:35 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantRestricted Stock Unit · Derivative | 9,719 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-007671 · doc4.xml · derivative · entry 5 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,719 Underlying: Common Stock · 9,719 shares Expires not disclosed F9 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. F10 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 6, 2021, February 6, 2022, February 6, 2023, and February 6, 2024. F10 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 6, 2021, February 6, 2022, February 6, 2023, and February 6, 2024. Read SEC document |
| February 06, 2020 Filed Feb 7, 2020 23:35 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantStock Option · Derivative | 61,347 | $0.00 Strike: $102.90 | $0.00 |
DisclosureSEC source: 0001209191-20-007671 · doc4.xml · derivative · entry 4 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,347 Underlying: Common Stock · 61,347 shares Expires 2030-02-06 F8 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable March 6, 2020 and an additional 1/48th of the shares underlying the option becomes vested and excercisable each month thereafter. Read SEC document |
| February 06, 2020 Filed Feb 7, 2020 23:35 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 1,395 | $101.48 | $141,560.83 |
DisclosureSEC source: 0001209191-20-007671 · doc4.xml · nonDerivative · entry 3 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,262 F6 · kind: Sale of 1,395 shares of common stock issued upon vesting of 2,650 restricted stock units on February 6, 2020 to cover payroll and withholding taxes, with the balance of the shares (1,255) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F7 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $100.12 to $103.01. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 23:35 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 809 | $102.90 | $83,247.88 |
DisclosureSEC source: 0001209191-20-007671 · doc4.xml · nonDerivative · entry 2 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,007 F4 · kind: Sale of 809 shares of common stock issued upon vesting of 1,537 restricted stock units on February 5, 2020 to cover payroll and withholding taxes, with the balance of the shares (728) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F5 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $102.18 to $103.79. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 23:35 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 1,145 | $103.11 | $118,063.35 |
DisclosureSEC source: 0001209191-20-007671 · doc4.xml · nonDerivative · entry 1 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,279 F1 · kind: Sale of 1,145 shares of common stock issued upon vesting of 2,175 restricted stock units on February 5, 2020 to cover payroll and withholding taxes, with the balance of the shares (1,030) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $102.14 to $105.14. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · balance_after: Includes a total of 339 shares acquired under the Neurocrine Biosciences 2018 Employee Stock Purchase Plan, consisting of 166 shares on February 28, 2019 and 173 shares on August 30, 2019. Read SEC document |
| July 15, 2019 Filed Jul 17, 2019 23:06 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 5,835 | $87.44 | $510,201.31 |
DisclosureSEC source: 0001209191-19-042520 · doc4.xml · nonDerivative · entry 1 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,910 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $86.02 to $88.50 The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 07, 2019 Filed Feb 8, 2019 22:06 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantRestricted Stock Unit · Derivative | 15,423 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-008628 · doc4.xml · derivative · entry 3 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,423 Underlying: Common Stock · 15,423 shares Expires not disclosed F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. F5 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 7, 2020, February 7, 2021, February 7, 2022, and February 7, 2023. F5 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 7, 2020, February 7, 2021, February 7, 2022, and February 7, 2023. Read SEC document |
| February 07, 2019 Filed Feb 8, 2019 22:06 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantStock Option · Derivative | 83,341 | $0.00 Strike: $81.05 | $0.00 |
DisclosureSEC source: 0001209191-19-008628 · doc4.xml · derivative · entry 2 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,341 Underlying: Common Stock · 83,341 shares Expires 2029-02-07 F3 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 7, 2019 and an additional 1/48th of the shares underlying the option becomes vested and excercisable each month thereafter. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 22:06 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 920 | $83.57 | $76,883.02 |
DisclosureSEC source: 0001209191-19-008628 · doc4.xml · nonDerivative · entry 1 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,745 F1 · kind: Sale of 920 shares of common stock issued upon vesting of 2,650 restricted stock units on February 6, 2019 to cover payroll and withholding taxes, with the balance of the shares (1,730) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $80.80 to $84.9755. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 05, 2019 Filed Feb 6, 2019 22:59 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 755 | $87.95 | $66,401.04 |
DisclosureSEC source: 0001209191-19-007846 · doc4.xml · nonDerivative · entry 2 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,015 F3 · kind: Sale of 755 shares of common stock issued upon vesting of 2,175 restricted stock units on February 5, 2019 to cover payroll and withholding taxes, with the balance of the shares (1,420) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F4 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $87.46 to $88.42. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 05, 2019 Filed Feb 6, 2019 22:59 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 602 | $88.08 | $53,025.67 |
DisclosureSEC source: 0001209191-19-007846 · doc4.xml · nonDerivative · entry 1 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,595 F1 · kind: Sale of 602 shares of common stock issued upon vesting of 1,537 restricted stock units on February 5, 2019 to cover payroll and withholding taxes, with the balance of the shares (935) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $87.46 to $88.58. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| June 01, 2018 Filed Jun 5, 2018 22:53 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 12,350 | $97.34 | $1,202,163.82 |
DisclosureSEC source: 0001209191-18-035925 · doc4.xml · nonDerivative · entry 1 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,690 F1 · kind: Sale of 12,350 shares of common stock issued upon vesting of 25,000 restricted stock units on June 1, 2018 to cover payroll and withholding taxes, with the balance of the shares (12,650) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $95.80 to $98.49. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 06, 2018 Filed Feb 7, 2018 23:00 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Tax withholdingCommon Stock | 917 | $82.48 | $75,634.16 |
DisclosureSEC source: 0001209191-18-008206 · doc4.xml · nonDerivative · entry 2 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,310 F3 · kind: Payment of tax liability by withholding 917 shares of Common Stock incident to the vesting of a security issued in accordance with Rule 16b-3, with the balance of the shares (1,733) maintained by the Reporting Person. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 23:00 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantRestricted Stock Unit · Derivative | 12,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-008206 · doc4.xml · derivative · entry 5 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,250 Underlying: Common Stock · 12,250 shares Expires 2021-03-15 F5 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Neurocrine Common Stock. F7 · derivative.exercise_date: A portion of this Performance based Restricted Stock Units ("PRSU") will vest upon FDA approval of opicapone within a specified time period, and portions of this PRSU will vest upon achievement of specified revenue milestones within a specified time period. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 23:00 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantRestricted Stock Unit · Derivative | 6,150 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-008206 · doc4.xml · derivative · entry 4 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,150 Underlying: Common Stock · 6,150 shares Expires not disclosed F5 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Neurocrine Common Stock. F6 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 5, 2019, February 5, 2020, February 5, 2021, and February 5, 2022. F6 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 5, 2019, February 5, 2020, February 5, 2021, and February 5, 2022. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 23:00 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantStock Option · Derivative | 34,750 | $0.00 Strike: $81.49 | $0.00 |
DisclosureSEC source: 0001209191-18-008206 · doc4.xml · derivative · entry 3 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,750 Underlying: Common Stock · 34,750 shares Expires 2028-02-05 F4 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 5, 2018 and an additional 1/48th of the shares underlying the option becomes vested and excercisable each month thereafter. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 23:00 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 820 | $83.14 | $68,174.23 |
DisclosureSEC source: 0001209191-18-008206 · doc4.xml · nonDerivative · entry 1 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,577 F1 · kind: Sale of 820 shares of common stock issued upon vesting of 2,175 restricted stock units on February 5, 2018 to cover payroll and withholding taxes, with the balance of the shares (1,355) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $81.98 to $84.41. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 07, 2017 Filed Feb 9, 2017 00:40 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 132 | $44.65 | $5,893.80 |
DisclosureSEC source: 0001209191-17-008911 · doc4.xml · nonDerivative · entry 2 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,222 F1 · kind: Sale of 821 and 132 shares of common stock issued upon vesting of 2175 restricted stock units to cover withholding taxes with the balance of the shares (1222) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Read SEC document |
| February 06, 2017 Filed Feb 9, 2017 00:40 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantRestricted Stock Option · Derivative | 10,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-008911 · doc4.xml · derivative · entry 4 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,600 Underlying: Common Stock · 10,600 shares Expires not disclosed F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Neurocrine Common Stock. F5 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 6, 2018, February 6, 2019, February 6, 2020, and February 6, 2021. F5 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 6, 2018, February 6, 2019, February 6, 2020, and February 6, 2021. Read SEC document |
| February 06, 2017 Filed Feb 9, 2017 00:40 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantStock Option · Derivative | 76,800 | $0.00 Strike: $43.24 | $0.00 |
DisclosureSEC source: 0001209191-17-008911 · doc4.xml · derivative · entry 3 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,800 Underlying: Common Stock · 76,800 shares Expires 2027-02-06 F3 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 6, 2017 and an additional 1/48th of the shares underlying the option becomes vested and excercisable each month thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.